Denali Therapeutics (NASDAQ: DNLI) revenue
Denali Therapeutics reported revenue of $0.0m for fiscal 2025; in fiscal 2024 it was $0.0m.
Denali Therapeutics's best year of the last 9 was fiscal 2020. The biggest drop was in fiscal 2021, −85.5%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $0.0m | — | −$555.3m | — |
| 2024 | $0.0m | −100.0% | −$487.3m | — |
| 2023 | $330.5m | +204.7% | −$196.7m | −59.5% |
| 2022 | $108.5m | +122.9% | −$340.7m | −314.2% |
| 2021 | $48.7m | −85.5% | −$295.8m | −607.8% |
| 2020 | $335.7m | +1,158.2% | $62.7m | 18.7% |
| 2019 | $26.7m | −79.3% | −$213.2m | −799.1% |
| 2018 | $129.2m | — | −$46.4m | −35.9% |
| 2017 | $0.0m | — | −$90.1m | — |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Denali Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Denali Therapeutics ranks 407th of the 422 US health care companies with a page on Celsmar.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 405th | Capricor Therapeutics | $0.0m | −100.0% |
| 406th | Compass Therapeutics | $0.0m | −100.0% |
| 407th | Denali Therapeutics | $0.0m | — |
| 408th | Design Therapeutics | $0.0m | — |
| 409th | Fulcrum Therapeutics | $0.0m | −100.0% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Denali Therapeutics
- How much revenue did Denali Therapeutics make in fiscal 2025?
- Denali Therapeutics reported revenue of $0.0m for fiscal 2025, compared with $0.0m in fiscal 2024.
- What was the best year for revenue at Denali Therapeutics?
- Of its last 9 fiscal years, fiscal 2020, with $335.7m.
- Where does Denali Therapeutics rank in its sector by revenue?
- It ranks 407th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Denali Therapeutics come from?
- From the annual report (Form 10-K) that Denali Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Denali Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019 · 2018 · 2017. More on Denali Therapeutics: the Denali Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.